H.F.M BY TICEBA
LIVE

Serial Number

79314148

Owner

Dr. Christoph Ganss

Attorney

Sean K. Owens

Filing Date

Apr 10, 2021

Add to watchlist:

No watchlists yet
View on USPTO

H.F.M BY TICEBA Trademark

Serial Number: 79314148 • Registration: 6959288

H.F.M BY TICEBA is a trademark filed by Dr. Christoph Ganss on April 10, 2021. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Dr. Christoph Ganss (4 trademarks)

Im Bäckerfeld 2
69120 Heidelberg , DE

Entity Type: 01

Trademark Details

Filing Date

April 10, 2021

Registration Date

January 24, 2023

Published for Opposition

November 8, 2022

Goods & Services

Pharmaceutical drugs, namely, pharmaceutical drugs for treatment of skin diseases, antibiotics, immune suppressants, anti-inflammatory pharmaceuticals; Pharmaceutical drugs for treatment of disease and disorders of the respiratory system, the gastrointestinal system, the endocrine system, the cardiovascular system, the nervous system, the musculoskeletal system, the urinary system, the integumentary system, the reproductive system, for the treatment of blood diseases and disorders; Pharmaceutical and veterinary preparations for treatment of vertigo, migraine, nausea, vomiting, for treatment of skin diseases, wound healing; Pharmaceutical preparations for anti-aging; Diagnostic agents for medical use; Preparations for medical purposes, namely, for the treatment of skin diseases; Substances for medical use, namely, for regeneration of tissue and anti-inflammation; Stem cells for medical purposes; Stem cells for veterinary purposes; Stem cells for aesthetic purposes, namely, for anti-aging, for use in dermatology procedures; Somatic stem cell therapeutics, namely, for medical therapeutic use; Fibroblasts for medical use; Fibroblasts for aesthetic purposes, namely, for use in dermatology procedures; Pharmaceutical implants, namely, implantable surgery bones, bone grafts, cells, bone marrow; Surgical implants derived from stem cells, namely, surgical implants derived from living tissues and living stem cells; Surgical implants derived from fibroblasts, namely, surgical implants comprised of living fibroblasts tissue cells; Biological tissue for implantation, namely, implants comprising living tissues; Cell growth media for growing cells for medical use; Pharmaceutical preparations for tissue regeneration; Vascular grafts; Living tissue, namely, surgical implants comprised of living tissues; Biotechnologically engineered tissue products, namely, cell sheets/plasters for wound healing/burns, eye lense grafts, bone grafts, biological tissue grafts, human allograft tissue

Stem cells for scientific or research use; cell growth media for growing cells for scientific use

Medical services relating to the removal, treatment, processing and preservation of medical cells and human tissue, stem cells and bone marrow, also in the field of regenerative medicine, including tissue engineering; medical services in connection with the removal, treatment and processing of human tissue and stem cells, human tissue and stem cell bank services, including in the field of regenerative medicine, including tissue engineering; medical services relating to the cultivation and extraction of stem cells; medical services in connection with the cultivation and extraction of stem cells

Stem cell research; scientific research and development and medical research and development in the field of stem cells; Scientific research, testing and analysis services in the field of regenerative medicine and tissue engineering; Scientific research for medical purposes; Medical research; Research and development of new products for others; Consultancy in the field of pharmaceutical research; Providing information on medical and scientific research on pharmaceutical products; Biomedical research; Preparation of reports relating to scientific research, namely, technical writing for others; Research in the field of biotechnology; Research in the field of gene therapy; Research and development in the field of immunology; Research and development in the field of antibodies; Research and development in the field of antibody technology; Research and development in the field of bacteriology; Research and development in the field of gene expression systems; Research and development in the field of vaccines; Research and development services for the pharmaceutical industry; Research and development services in the field of biotechnology; Development of industrial processes, namely, engineering of industrial processes to manufacture stem cells; Development of industrial processes, namely, in the field of regenerative medicine and tissue engineering;Industrial process research in the field of regenerative medicine, tissue engineering, chemical engineering

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
May 23, 2023 FINO
FINAL DISPOSITION NOTICE SENT TO IB
May 1, 2023 FICS
FINAL DISPOSITION PROCESSED
May 1, 2023 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Apr 24, 2023 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jan 24, 2023 NRCC
REGISTERED-PRINCIPAL REGISTER
Jan 24, 2023 R.PR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Dec 20, 2022 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Nov 30, 2022 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Nov 30, 2022 OPNR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 8, 2022 NPUB
PUBLISHED FOR OPPOSITION
Nov 8, 2022 PUBO
NOTIFICATION PROCESSED BY IB
Nov 7, 2022 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Oct 19, 2022 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Oct 19, 2022 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Oct 19, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 29, 2022 CNSA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 29, 2022 GNRN
NON-FINAL ACTION E-MAILED
Sep 29, 2022 GNRT
NON-FINAL ACTION WRITTEN
Sep 29, 2022 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 9, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 9, 2022 CRFA
ASSIGNED TO LIE
Aug 9, 2022 ALIE
NOTICE OF REVIVAL - E-MAILED
Jul 13, 2022 NREV
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 13, 2022 TROA
PETITION TO REVIVE-GRANTED
Jul 13, 2022 PETG
TEAS PETITION TO REVIVE RECEIVED
Jul 13, 2022 PROA
ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Jul 13, 2022 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Jul 13, 2022 ABN2
REFUSAL PROCESSED BY IB
Jan 15, 2022 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Dec 28, 2021 RFCS
REFUSAL PROCESSED BY MPU
Dec 28, 2021 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Dec 2, 2021 RFCR
NON-FINAL ACTION WRITTEN
Dec 1, 2021 CNRT
ASSIGNED TO EXAMINER
Nov 30, 2021 DOCK
APPLICATION FILING RECEIPT MAILED
Jul 2, 2021 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 28, 2021 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jun 25, 2021 REPR